Champions Oncology (NASDAQ:CSBR) Stock Crosses Below Two Hundred Day Moving Average - What's Next?

Key Points

• Champions Oncology shares fell below their 200-day moving average, trading as low as $5.00 versus the $5.85 average, signaling continued technical weakness.
• Analyst sentiment remains negative: Weiss Ratings downgraded the stock to “sell (e+),” while MarketBeat reports an average rating of “Sell.”
• The company exceeded quarterly expectations, reporting EPS of $0.01 versus the forecasted loss of $0.05 and revenue of $13.84 million versus estimates of $12.89 million, though it still posted a negative net margin and return on equity.

Champions Oncology, Inc. (NASDAQ:CSBR - Get Free Report) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.85 and traded as low as $5.00. Champions Oncology shares last traded at $5.00, with a volume of 2,050 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Champions Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Champions Oncology has an average rating of "Sell".

Champions Oncology Stock Performance

The company's 50 day moving average price is $5.58 and its 200 day moving average price is $5.85. The company has a market cap of $69.60 million, a price-to-earnings ratio of -62.50 and a beta of 0.40.

Champions Oncology (NASDAQ:CSBR - Get Free Report) last announced its earnings results on Monday, July 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.06. The business had revenue of $13.84 million during the quarter, compared to analysts' expectations of $12.89 million. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Champions Oncology by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company's stock worth $2,158,000 after acquiring an additional 6,229 shares in the last quarter. Mink Brook Asset Management LLC acquired a new stake in Champions Oncology during the 4th quarter valued at $555,000. Acadian Asset Management LLC raised its position in Champions Oncology by 28.7% in the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 8,814 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in Champions Oncology in the 1st quarter valued at $201,000. Finally, Jane Street Group LLC acquired a new position in Champions Oncology in the first quarter worth $200,000. Institutional investors own 41.30% of the company's stock.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source